Ray Dalio
VKTX icon

Ray Dalio’s Viking Therapeutics VKTX Stock Holding History

Ray Dalio’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Sell
71,229
-32,430
-31% -$1.04M 0.01% 623
2025
Q4 		$3.65M Sell
103,659
-19,832
-16% -$703K 0.01% 618
2025
Q3 		$3.25M Buy
+123,491
New +$3.68M 0.01% 594

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ray Dalio's VKTX Position: Q1 2026 in Review

Ray Dalio reduced its Viking Therapeutics (VKTX) stake by 31% in Q1 2026, selling an estimated $1.04M and leaving 71,229 shares worth $2.32M. The position accounts for 0.01% of the portfolio, ranked #623.

Ray Dalio first reported a position in VKTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.65M in Q4 2025. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Ray Dalio held 71,229 shares of Viking Therapeutics worth $2.32M as of Q1 2026.
  • Ray Dalio sold 32,430 Viking Therapeutics shares in Q1 2026, an estimated $1.04M.
  • Viking Therapeutics made up 0.01% of Ray Dalio's portfolio in Q1 2026, its #623 holding.
  • Ray Dalio first reported a position in Viking Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Ray Dalio's Viking Therapeutics position peaked at $3.65M in Q4 2025.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.